🇺🇸 FDA
Pipeline program

REGN7544

R7544-SIH-2435

Phase 2 small_molecule completed

Quick answer

REGN7544 for Sepsis-Induced Hypotension is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Sepsis-Induced Hypotension
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials